Motavizumab's Data Integrity Worries Grow As FDA Shows Interest In Lawsuit
Executive Summary
Alongside FDA's concerns about possible bias in the Phase III clinical trials of Rezield (motavizumab), MedImmune faces an accusation of data suppression from a former employee who alleges he was fired for bringing up problems with sample screening
You may also be interested in...
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA's request for another clinical trial before approving MedImmune's Rezield for prevention of respiratory syncytial virus could reflect an advisory committee's recommendations that the company show some advantage over its currently approved RSV agent, Synagis, particularly in sicker children
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA's request for another clinical trial before approving MedImmune's Rezield for prevention of respiratory syncytial virus could reflect an advisory committee's recommendations that the company show some advantage over its currently approved RSV agent, Synagis, particularly in sicker children
AstraZeneca's Rezield Hits Another Regulatory Wall
FDA issues a second "complete response" letter for the respiratory syncytial virus prophylaxis agent, this time seeking a new clinical trial.